Overview

The Gene Technology Act 2000 was enacted to regulate the use, handling, and release of genetically modified organisms (GMOs) in Australia, aiming to address issues related to the protection of human health and the environment. The Act establishes a framework for the assessment and approval of activities involving GMOs, ensuring that such activities are conducted with appropriate safety measures. The policy objective of the Act is to balance the benefits of genetic technology with the need to protect human health and the environment. The Act is administered by the Office of the Gene Technology Regulator, which evaluates applications for activities involving GMOs and makes decisions based on risk assessments and management plans. This legislative framework allows for the controlled use of GMOs while mitigating potential risks.

Scope and Application

The proposed field trial of genetically modified perennial ryegrass, as detailed in the gazette C2022G01183, applies specifically to Grasslanz Technology Australia Pty Limited, a private entity engaged in the development of genetically modified organisms. This trial, which is intended to assess the potential of perennial ryegrass with enhanced metabolisable energy content, is subject to the oversight and approval of the Gene Technology Regulator. The scope of the legislation encompasses the environmental and health risk assessments necessary for the proposed trial, which is set to occur within specified boundaries in New South Wales, Victoria, Queensland, and Western Australia, across multiple sites over a period of five years. Notably, the genetically modified ryegrass will not be used for human consumption or commercial animal feed, thereby limiting its application to research and development purposes only. The legislation invites public comment on the risk assessment and management plans, ensuring transparency and public participation in the decision-making process before any licence is issued. Submissions are to be directed to the Office of the Gene Technology Regulator and must reference DIR 194, with a deadline of 17 January 2023.

Key Provisions

The Gene Technology Act 2000 (Cth) governs the regulation of genetically modified (GM) organisms in Australia, including the assessment and licensing of activities such as field trials (section 3). In the context of the proposed field trial of genetically modified perennial ryegrass by Grasslanz Technology Australia Pty Limited, the Act sets out the requirements for the Regulator to assess the application and prepare a Risk Assessment and Risk Management Plan (RARMP) (section 6). The RARMP for this application, which evaluates the potential risks to human health and the environment, is open for public comment and submission before the Regulator makes a decision on whether to issue a licence (section 11). Parties or entities governed by the Act, such as the applicant, must comply with the requirements set out in the Act and the RARMP, including conducting the field trial in accordance with the conditions specified in the licence (section 6(3)). The applicant must also ensure that the GM perennial ryegrass is not used for human food or commercial animal feed during the trial, as specified in the application (Gazette). Furthermore, the applicant must monitor the trial sites and report any adverse effects on human health and the environment to the Regulator (section 11). Failure to comply with the requirements of the Act or the conditions of a licence may result in civil or criminal penalties. Under the Gene Technology Act 2000 (Cth), a person who contravenes a direction or condition in a licence may be liable for a civil penalty of up to $66,000 per day for a continuing contravention, or $1,100 per day for a non-continuing contravention (section 35). Additionally, a person who engages in activities involving GM organisms without a licence or in breach of the terms of a licence may be subject to criminal penalties, including fines of up to $5.5 million and/or imprisonment for up to 10 years (section 36). These penalties reflect the seriousness of non-compliance with the Act and the importance of protecting human health and the environment from potential risks associated with GM organisms.